Company intelligence / Profile preview

Anaveon

Basel, Basel-Stadt, Switzerlandanaveon.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Anaveon's lead compound ANV419 has demonstrated the ability to deliver high-dose IL‑2 with a favorable safety and tolerability profile in patients with advanced solid tumors. As of March 2023, data from a Phase I study showed good safety and promising immunological activity. ANV419 has progressed into multiple Phase II studies targeting various cancer indications. Follow-on compounds such as ANV600 and ANV700 are advancing through preclinical and early clinical development, focusing on novel mechanisms to enhance anti-tumor immunity or reverse T-cell exhaustion.

Therapeutic areas: OncologyImmunology
Modalities: Cytokine-based biologics (including IL-2/anti–IL-2 antibody fusion proteins)Protein engineeringSelective cytokine receptor agonistsBispecifics (e.g., PD‑1 targeted therapeutics)
Industry: Biotech

Drug pipeline

4 assets

ANV419

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Anaveon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anaveon.

Explore the full profile